The American journal of managed care
-
Direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) lead to cure in more than 95% of recipients; however, payers may limit access to these lifesaving drugs due to high initial cost. Here, the cost-effectiveness of treating HCV with DAAs vs no treatment over a lifetime horizon is evaluated from the perspective of Kaiser Permanente Southern California (KPSC). ⋯ DAA treatment at KPSC is predicted to significantly reduce HCV-related morbidity and mortality, providing an anticipated return on investment in drug costs after 3 years of treatment.
-
To quantify the impact of 1-star reviews across multiple physician rating websites (PRWs) on new patient volume. ⋯ Given the limited yet longitudinal negative impact of 1-star reviews and the growing influence of PRWs, physicians should consider the magnitude of the effect as they consider responding to bad reviews.
-
Commercial health insurers can participate in the rapidly growing Medicare Advantage (MA) market, which may affect network formation and prices in traditional commercial insurance markets. We aim to quantify the prevalence and growth of commercial insurers participating in MA within the same state. ⋯ By 2021, almost all ESI enrollees were covered by insurers who participated in MA in the same state. Future research should investigate how insurer participation in MA affects network formation and prices in commercial markets.
-
Existing studies have shown the benefits of second-generation antidiabetic medications in patients with type 2 diabetes (T2D). However, the medications' real-world utilization was not well understood. Our study assessed patient factors associated with the use of second-generation antidiabetic medications in a nationally representative sample of patients with T2D. ⋯ The uptake of second-generation antidiabetic medications was 14% among patients with T2D in the United States. Prescription benefit design that targets lower out-of-pocket payments for these newer drugs may improve patient access and clinical outcomes for patients with T2D.
-
Correction to the article "Antineutrophil Cytoplasmic Antibody (ANCA) Vasculitis: Pathophysiology, Diagnosis, and the Evolving Treatment Landscape" published in a September 2021 supplement to The American Journal of Managed Care.